Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
Conditions
- Chronic Myeloproliferative Disorders
- Graft Versus Host Disease
- Infection
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms
- Precancerous Condition
- Secondary Myelofibrosis
- Small Intestine Cancer
Interventions
- BIOLOGICAL: anti-thymocyte globulin
- DRUG: cyclophosphamide
- DRUG: etoposide
- DRUG: fludarabine phosphate
- DRUG: melphalan
- DRUG: methotrexate
- DRUG: sirolimus
- DRUG: tacrolimus
- PROCEDURE: allogeneic hematopoietic stem cell transplantation
- PROCEDURE: hematopoietic stem cell transplantation
- PROCEDURE: nonmyeloablative allogeneic hematopoietic stem cell transplantation
- PROCEDURE: peripheral blood stem cell transplantation
- RADIATION: total-body irradiation
Sponsor
City of Hope Medical Center
Collaborators